By Kathryn Hardison
Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal.
The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday.
The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticker ELVN.
The combined company is expected to have about $300 million of cash and cash equivalents at closing, after transaction expenses. That should advance Enliven's pipeline through multiple clinical milestones and provide runway into early 2026, the companies said.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 13, 2022 17:45 ET (21:45 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。